Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human beta-defensin 3
- Development stage
- Preclinical
- Lead developer
- Case Western Reserve University
- Modality
- Peptides
- Administration
- Topical, Intratumoral, Implant
01
Overview
Human beta-defensin 3 (HBD-3) is a 5 kDa cationic antimicrobial peptide (AMP) that plays a critical role in the innate immune system. It is expressed in various epithelial tissues and is characterized by its broad-spectrum activity against bacteria, including multi-drug resistant strains like MRSA, as well as fungi and viruses. HBD-3 functions primarily by disrupting microbial membranes through electrostatic interactions. Additionally, it serves as an immunomodulator by acting as a ligand for C-C chemokine receptor type 6 (CCR6), thereby recruiting dendritic cells and T cells to sites of infection. Recent research has also explored its role in oncology, specifically in glioblastoma, where it appears to influence the self-renewal capacity of glioma stem cells in a context-dependent manner. While it is a subject of significant therapeutic interest for infectious diseases and wound healing, it currently remains in the preclinical research stage.
- Other names
- beta-defensin 103beta-defensin103beta-defensin-103BD-3BD3BD 3HBD3HBD-3HBD 3
02
Targets
Peptidoglycan biosynthesis machinery (membrane-associated)CCR6 (C-C motif chemokine receptor 6)Negatively charged microbial membrane lipids and anionic surface polymers
Beyond the preview
Go deeper on human beta-defensin 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human beta-defensin 3.